futuximab

06/01/2015 - "Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer."
06/01/2015 - "Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. "
01/01/2020 - "Sym004 serum concentration data from 330 cancer patients participating in four Phase 1 and 2 trials (n = 247 metastatic colorectal cancer, n = 87 various types advanced solid tumors) were pooled for non-linear mixed effects modeling. "
06/01/2015 - "In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhibitor resistance were enrolled; 17 of 39 patients (44%) had tumor shrinkage, with 5 patients (13%) achieving partial response. "
01/01/2016 - "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."

07/01/2018 - "Previous studies have shown that Sym004 is more efficient at inducing internalization and degradation of EGFR than individual components, which translates into superior cancer cell inhibition. "
07/01/2015 - "This trial revealed modest anti-tumor activity of Sym004 in extensively pretreated advanced SCCHN patients."
01/01/2020 - "The full covariate model including all plausible covariates included in a single step showed no impact on Sym004 exposure of age, Asian race, renal and hepatic function, tumor type and previous anti-EGFR treatments. "
01/01/2020 - "Sym004 has been clinically tested for treatment of solid tumors. "
10/01/2018 - "Patients in Part A (dose escalation) had refractory or recurrent late-stage solid tumors and received Sym004 6 mg/kg/wk (n = 3), 9 mg/kg loading/6 mg/kg/wk (n = 6), 12 mg/kg/wk (n = 6), or 18 mg/kg biweekly (n = 6). "

02/14/2017 - "Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines."
10/01/2018 - "Patients in expansion Part B (n = 30) had esophageal squamous cell carcinoma and received Sym004 at the dose recommended from Part A. "

02/14/2017 - "Because EGFR is highly expressed in the majority of esophageal squamous cell carcinomas (ESCCs), we investigated the efficacy of Sym004 in human ESCC cell lines. "

12/01/2013 - "Taken together, these data reveal the strong capacity of Sym004 to augment radiation response in lung and head and neck cancers. "
12/01/2013 - "Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers."
12/01/2013 - "In the current study, we examine the capacity of Sym004 to augment radiation response in lung cancer and head and neck cancer model systems. "
01/01/2020 - "Consistently Sym004 efficacy and potentiation of cisplatin responses correlated with EGFR surface expression in head and neck cancer cells. "